Hong Kong With Asia-Pacific poised to become a global force in cell and gene therapy, Xellera Therapeutics is positioning itself at the heart of this transformation. Led by CEO Camie Chan, the Hong Kong-based company is bridging critical infrastructure gaps by offering GMP-certified manufacturing, regulatory compliance aligned with global standards, and a…
Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…
Switzerland Founded in 2017 by a group of biotech veterans with deep expertise in antibody engineering, CDR-Life has evolved into a platform-driven company advancing next-generation T-cell engagers for oncology and autoimmune disease. With assets progressing through clinical trials and a strategic partnership already in place, CEO Christian Leisner discusses how the…
Switzerland From its roots as a family-run ophthalmology business to its bold reinvention as a precision oncology biotech, CIS Biopharma is charting a distinctive course through the rapidly evolving life sciences landscape. Leading this transformation, CEO Christoph Schäfer shares the strategic rationale behind the company’s evolution, offering insight into how scientific…
Hong Kong A long-standing figure in Hong Kong’s haematology landscape, Professor Kenny Lei has played a pivotal role in advancing lymphoma care and cellular therapies over the past three decades. His contributions span the early adoption of autologous peripheral blood stem cell transplantation and active involvement in establishing the city’s first hospital-based…
Switzerland Five decades since its founding, Helsinn has recently undergone one of the most consequential transformations in its history. Executive Chairman Riccardo Braglia and Group CEO Melanie Rolli reflect on a period marked by strategic separation, operational reinvention, and renewed therapeutic ambition. From navigating a near-collapse to redefining the company’s role…
Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…
Hong Kong In our field, success is not defined by short-term remission alone, but by long-term disease eradication. Our goal is always a cure, not prolonged management. After decades spent advancing paediatric oncology in Hong Kong, Professor Li Chi Kong has increased his focus toward the frontier of cell and gene therapies, spearheading…
Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…
Europe Stefan Barbour describes how personal loss and a multicultural, healthcare-focused background have driven a lifelong commitment to access to medicines. Now leading BeiGene’s diverse 22-country Sub Region Europe, a grouping he built from scratch, Barbour outlines his leadership style that blends trust, accountability and “aggressive talent development;” and explains how…
Saudi Arabia Leading through transformation requires more than strategic clarity – it demands cultural fluency, consistency of purpose, and the trust of an entire ecosystem. Abed Sabra has spent over 25 years at Roche embodying those principles, guiding the company’s evolution in Saudi Arabia at a time when healthcare is becoming a…
Saudi Arabia Mohamed Fawzy, Country President for Pfizer Saudi Arabia, discusses the company’s evolving role in supporting the Kingdom’s rapidly transforming healthcare sector. He shares insights on Pfizer’s local footprint, its contributions to public health through innovative vaccines and oncology treatments, and the company’s commitment to talent development and localization. Fawzy also…
See our Cookie Privacy Policy Here
